CI
NKTR icon

Cigna Investments’s Nektar Therapeutics NKTR Stock Holding History

Cigna Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-482
Closed -$243K – 693
2019
Q1 		$243K Buy
+482
New +$286K 0.03% 590
2018
Q3 		– Sell
-339
Closed -$249K – 774
2018
Q2 		$249K Sell
339
-42
-11% -$48.4K 0.02% 638
2018
Q1 		$607K Buy
381
+7
+2% +$9.02K 0.04% 386
2017
Q4 		$335K Buy
+374
New +$221K 0.02% 650

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cigna Investments's NKTR Position: Q2 2019 in Review

Cigna Investments sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 482 shares — an estimated $243K sold.

Cigna Investments first reported a position in NKTR in Q4 2017 and held it in 4 quarters. The position peaked at $607K in Q1 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

  • Cigna Investments reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cigna Investments sold 482 Nektar Therapeutics shares in Q2 2019, an estimated $243K.
  • Cigna Investments first reported a position in Nektar Therapeutics in Q4 2017 and held it in 4 quarters.
  • Cigna Investments's Nektar Therapeutics position peaked at $607K in Q1 2018.
  • 336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on Cigna Investments's 13F filing for Q2 2019, filed 12 Aug 2019.